Newly Formed Oligodendrocytes (Nfols) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Newly formed oligodendrocytes (NFOLs) are the immediate progeny of oligodendrocyte precursor cells (OPCs) that have recently committed to the oligodendrocyte lineage and begun the differentiation process. These cells represent a critical transitional stage in the oligodendrocyte developmental continuum, bridging OPCs to mature, myelinating oligodendrocytes[1].
In the context of neurodegeneration, NFOLs play essential roles in remyelination attempts, which occur as a compensatory response to demyelination in diseases such as multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Understanding NFOL biology is crucial for developing therapeutic strategies aimed at enhancing endogenous remyelination[2].
The oligodendrocyte lineage proceeds through distinct stages:
Key molecular events during OPC-to-NFOL transition[3]:
NFOLs express a combination of markers:
NFOLs have distinct metabolic features:
NFOLs are the cells that will become mature myelinating oligodendrocytes:
Oligodendrocytes provide metabolic support to neurons:
In MS, NFOLs represent the remyelination response[4]:
Oligodendrocyte dysfunction in AD includes[5]:
In PD, NFOLs and oligodendrocytes are affected:
NFOLs respond to demyelination after TBI:
Drug development focuses on[6]:
Strategies include:
Approaches include:
The study of Newly Formed Oligodendrocytes (Nfols) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Evidence from SEA-AD paper analysis on oligodendrocytes
Telencephalic OPCs are more proliferative, differentiate more frequently, and form a larger population relative to oligodendrocytes, explaining lower proportion of mature Type 2 oligodendrocytes
Supporting evidence:
Pick's disease tau exists as distinct conformational strains in different cell types (neurons, astrocytes, oligodendrocytes) within the same brain
Supporting evidence:
IL-12 (but not IL-23) signaling is the main driver of AD-specific neuroinflammation and alters neuronal and oligodendrocyte functions
Supporting evidence:
[67] Piwecka, Monika, Rajewsky, Nikolaus, Rybak-Wolf, Agnieszka (2023). Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease. https://doi.org/10.1038/s41582-023-00809-y
[93] Siletti, Kimberly et al. (2023). Transcriptomic diversity of cell types across the adult human brain. https://doi.org/10.1101/2022.10.12.511898
[101] Yang, Hyunjun et al. (2023). EMBER multidimensional spectral microscopy enables quantitative determination of disease- and cell-specific amyloid strains. https://doi.org/10.1073/pnas.2300769120
Bergles DE, Richardson WD. Oligodendrocyte development in the adult brain. Handb Clin Neurol. 2015;131:175-196. PMID:26563790. ↩︎
Franklin RJM, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9(11):839-855. PMID:18931697. ↩︎
Zhang Y, Argaw AT, Zabeau B, et al. The occupancy of oligodendrocyte lineage cells by newly formed oligodendrocytes in demyelinated lesions. J Neuroimmunol. 2019;332:62-70. PMID:30879742. ↩︎
Chang A, Nishiyama A, Peterson J, et al. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20(17):6404-6412. PMID:10964946. ↩︎
Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging. 2004;25(1):5-18. PMID:14675724. ↩︎
Najm FJ, Madhavan M, Zaremba A, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522(7555):216-220. PMID:25896324. ↩︎